Harbor Capital Advisors’s United Therapeutics UTHR Stock Holding History

Harbor Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$115K	Buy	213 +155	+267%	+$87.3K	0.01%	648
2026 Q1	$34K	Sell	58 -40	-41%	-$19.9K	﹤0.01%	719
2025 Q4	$48K	Buy	+98	New	+$45.6K	﹤0.01%	716
2023 Q3	–	Sell	-270	Closed	-$59.6K	–	643
2023 Q2	$59.6K	Buy	+270	New	+$59.8K	0.01%	478
2023 Q1	–	Sell	-313	Closed	-$87K	–	273
2022 Q4	$87K	Sell	313 -114	-27%	-$28.8K	0.08%	94
2022 Q3	$89K	Sell	427 -413	-49%	-$92.3K	0.08%	88
2022 Q2	$198K	Sell	840 -2	-0.2%	-$407	0.15%	81
2022 Q1	$151K	Buy	+842	New	+$160K	0.07%	146

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Harbor Capital Advisors's UTHR Position: Q2 2026 in Review

Harbor Capital Advisors increased its United Therapeutics (UTHR) stake by 267% in Q2 2026, buying an estimated $87.3K and bringing the position to 213 shares worth $115K. The position accounts for 0.01% of the portfolio, ranked #648.

Harbor Capital Advisors first reported a position in UTHR in Q1 2022 and has held it in 8 quarters since. The position peaked at $198K in Q2 2022. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Harbor Capital Advisors held 213 shares of United Therapeutics worth $115K as of Q2 2026.
Harbor Capital Advisors bought 155 United Therapeutics shares in Q2 2026, an estimated $87.3K.
United Therapeutics made up 0.01% of Harbor Capital Advisors's portfolio in Q2 2026, its #648 holding.
Harbor Capital Advisors first reported a position in United Therapeutics in Q1 2022 and has held it in 8 quarters since.
Harbor Capital Advisors's United Therapeutics position peaked at $198K in Q2 2022.
884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.